In-transit melanoma metastases: Evaluation and Management for the Dermatologist.

IF 12.8 1区医学 Q1 DERMATOLOGY

Journal of the American Academy of Dermatology Pub Date : 2025-03-10 DOI:10.1016/j.jaad.2025.03.005

Anagha Bangalore Kumar, James W Jakub, Scott C Lester, Svetomir N Markovic, Christian L Baum

引用次数: 0

Abstract

In-transit metastases (ITM) are estimated to occur in 5-10% of primary cutaneous melanomas. They are classified as stage III disease in the American Joint Committee on Cancer classification system and are associated with approximately a 30% 10-year survival rate. The management of ITM is not standardized. Treatment options depend on the number of lesions, location, distribution of ITM and general medical condition of the patient. Topical, local, regional, and systemic treatment options can be considered for treatment. Dermatologists may play a unique role in management through skin-directed therapies.

查看原文本刊更多论文

求助全文

约1分钟内获得全文求助全文

来源期刊

Journal of the American Academy of Dermatology 医学-皮肤病学

CiteScore

8.60

自引率

5.80%

发文量

2023

审稿时长

49 days

期刊介绍： The Journal of the American Academy of Dermatology (JAAD) is the official scientific publication of the American Academy of Dermatology (AAD). Its primary goal is to cater to the educational requirements of the dermatology community. Being the top journal in the field, JAAD publishes original articles that have undergone peer review. These articles primarily focus on clinical, investigative, and population-based studies related to dermatology. Another key area of emphasis is research on healthcare delivery and quality of care. JAAD also highlights high-quality, cost-effective, and innovative treatments within the field. In addition to this, the journal covers new diagnostic techniques and various other topics relevant to the prevention, diagnosis, and treatment of skin, hair, and nail disorders.